アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

schering plough limited - chlorhexidine gluconate cetrimonium bromide - cutaneous solution concentrate - non food animals - antiseptics

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - lidocaine 1 mg; tyrothricin 4 mg; cetrimonium bromide 2 mg - compressed lozenge - 4 mg - 1 mg - 2 mg - cetrimide 2 mg; lidocaine 1 mg; tyrothricin 4 mg - tyrothricin

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

bayer healthcare llc - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l), cetrimonium chloride (unii: uc9pe95ibp) (cetrimonium - unii:z7ff1xkl7a) - chlorhexidine gluconate 212.0 mg in 1 ml - for dermatological conditions responsive to chlorhexidine gluconate.

イスラエル - 英語 - Ministry of Health

inovamed ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 300 mg - quetiapine - quetiapine inovamed sr is indicated for the treatment of schizophrenia. quetiapine inovamed sr is effective in preventing relapse in stable schizophrenic patients who have been maintained on quetiapine inovamed sr. quetiapine inovamed sr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. quetiapine inovamed sr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy. prior to initiating treatment, clinicians should consider the safety profile of quetiapine inovamed sr.

イスラエル - 英語 - Ministry of Health

inovamed ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 150 mg - quetiapine - quetiapine inovamed sr is indicated for the treatment of schizophrenia. quetiapine inovamed sr is effective in preventing relapse in stable schizophrenic patients who have been maintained on quetiapine inovamed sr. quetiapine inovamed sr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. quetiapine inovamed sr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy. prior to initiating treatment, clinicians should consider the safety profile of quetiapine inovamed sr.

イスラエル - 英語 - Ministry of Health

inovamed ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 200 mg - quetiapine - quetiapine inovamed sr is indicated for the treatment of schizophrenia. quetiapine inovamed sr is effective in preventing relapse in stable schizophrenic patients who have been maintained on quetiapine inovamed sr. quetiapine inovamed sr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. quetiapine inovamed sr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy. prior to initiating treatment, clinicians should consider the safety profile of quetiapine inovamed sr.

イスラエル - 英語 - Ministry of Health

inovamed ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 400 mg - quetiapine - quetiapine inovamed sr is indicated for the treatment of schizophrenia. quetiapine inovamed sr is effective in preventing relapse in stable schizophrenic patients who have been maintained on quetiapine inovamed sr. quetiapine inovamed sr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. quetiapine inovamed sr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy. prior to initiating treatment, clinicians should consider the safety profile of quetiapine inovamed sr.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

viatris limited - influenza virus a/brisbane/02/2018 (h1n1) pdm09-like strain 15ug (a/brisbane/02/2018, ivr-190); influenza virus a/kansas/14/2017 (h3n2) like strain 15ug (a/kansas/14/2017, nymc x-327); influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a); influenza virus b/phuket/3073/2013 - like strain 15ug (b/ phuket/3073/2013, wild type) - suspension for injection - 0.5 ml - active: influenza virus a/brisbane/02/2018 (h1n1) pdm09-like strain 15ug (a/brisbane/02/2018, ivr-190) influenza virus a/kansas/14/2017 (h3n2) like strain 15ug (a/kansas/14/2017, nymc x-327) influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a) influenza virus b/phuket/3073/2013 - like strain 15ug (b/ phuket/3073/2013, wild type) excipient: calcium chloride dihydrate dibasic sodium phosphate as dihydrate 0.67 mg magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines. influvac tetra (saison 2019/2020) is indicated in adults and children 3 years of age and older at low risk of complications from influenza.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

wild child w a pty ltd - quassia amara 2x hpus (amargo 200mcg/g) - lice and egg treatment

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -